ArticlePurinergic signalling2026
The analgesic effect of electroacupuncture in alleviating paclitaxel-induced peripheral neuropathic pain and its possible mechanism relates to TLR4/P2X7-NLRP3 signaling pathway.
Article in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Paclitaxel-induced peripheral neuropathic pain (PIPNP) is a common and debilitating adverse effect of chemotherapy, with limited effective treatments. Electroacupuncture (EA) has demonstrated analgesic potential in various pain models, but its efficacy and mechanisms in PIPNP remain incompletely understood. This study aimed to evaluate the analgesic effect of EA in a murine model of PIPNP and investigate whether its mechanism involves modulation of the TLR4/P2X7-NLRP3 signaling pathway. A PIPNP model was established in male C57BL/6 J mice by intraperitoneal injection of paclitaxel (cumulative dose 8 mg/kg). Mice were randomly divided into control, PIPNP model, PIPNP with EA treatment at different intensities (0.5, 1.0, and 2.0 mA), and sham EA groups. Mechanical allodynia and thermal hyperalgesia were assessed using von Frey filaments and hot plate tests, respectively. Immunofluorescence staining and western blotting were employed to analyze the expression of pain-related neurotransmitters (substance P, CGRP, p75) and key components of the TLR4/P2X7-NLRP3 signaling pathway in plantar tissues, dorsal root ganglia (DRG), and spinal cord. EA treatment, particularly at 1.0 mA, significantly alleviated paclitaxel-induced mechanical allodynia and thermal hyperalgesia. Paclitaxel administration upregulated substance P, CGRP, and p75 in plantar tissues and activated the TLR4/P2X7-NLRP3 signaling pathway in DRG and spinal cord, as evidenced by increased expression of TLR4, P2X7, NLRP3, NF-κB, IL-1β, and IL-18. EA intervention markedly suppressed these changes, indicating its role in inhibiting neuroinflammation and modulating pain-related signaling. EA exerts analgesic effects in paclitaxel-induced neuropathic pain by attenuating the activation of the TLR4/P2X7-NLRP3 signaling pathway and reducing the expression of pain-related neurotransmitters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.